1. Clinical Overview of Humanin

Molecule: 24-amino acid peptide encoded within the mitochondrial 16S rRNA gene (MT-RNR2). First isolated from brain tissue of Alzheimer's disease patients.

Classification: Mitochondrial-derived peptide (MDP) · Cytoprotective / Anti-apoptotic peptide · Neuroprotective and anti-aging signaling molecule

Alternate Names: HN, Humanin Peptide, Mitochondrial-Derived Peptide (MDP)

Physiological Role

Neuronal protection
Anti-apoptotic intracellular signaling
Mitochondrial function and ATP production
Oxidative stress reduction
Insulin sensitization
Longevity and stress adaptation

Humanin communicates with nuclear receptors and systemic organs as a mitokine, providing protective signals that decline with age. A strong candidate for cognitive preservation, anti-aging, and metabolic health programs.

2. Mechanisms of Action

2.1 Anti-Apoptotic Signaling

Binds and inhibits pro-apoptotic proteins (Bax, tBid, IGFBP3)
Prevents mitochondrial membrane permeability transition (MPTP)
Reduces cytochrome c release and caspase activation

2.2 Mitochondrial Function Enhancement

Increases mitochondrial respiratory efficiency
Enhances cellular ATP generation
Reduces mitochondrial ROS production

2.3 Insulin Sensitization

Activates PI3K/Akt pathway in insulin-responsive tissues
Improves glucose uptake and insulin signaling in skeletal muscle and liver

2.4 Neuroprotective and Endocrine-Like Effects

Acts through a trimeric receptor (CNTFR/γc/WSX-1)
Reduces neuronal cell death in oxidative and ischemic conditions
Modulates IGF-1 and GH axis signaling indirectly

3. Evidence Summary — Clinical Domains

3.1 Cognitive Decline / Neurodegeneration

Neuroprotection in Alzheimer's and Parkinson's models, decreased amyloid-beta toxicity, preserved synaptic integrity and neuronal viability.

3.2 Aging & Mitochondrial Dysfunction

Humanin levels inversely correlate with age. Repletion reverses markers of frailty and metabolic decline. Promotes healthy mitochondrial turnover and longevity signaling.

3.3 Insulin Resistance & Metabolic Health

Improves insulin sensitivity and reduces hepatic glucose output. Protective against beta-cell apoptosis in the pancreas.

3.4 Cardiovascular Resilience

Reduces oxidative damage in endothelial cells. Improves post-ischemic cardiac function in preclinical models.

3.5 Stress Response / Cytoprotection

Enhances resilience under oxidative, metabolic, and inflammatory load. Emerging applications in chronic fatigue, neuroinflammation, and post-injury recovery.

4. Clinical Protocols

4.1 Route of Administration

Subcutaneous (preferred) · Intranasal (experimental)

4.2 Reconstitution

10 mg lyophilized vial · 2 mL bacteriostatic saline → 5 mg/mL · Or 4 mL → 2.5 mg/mL (flexible dosing)

4.3 Dosing Protocols

Standard Mitochondrial Optimization: 5–20 mg SC 3×/week or QOD · 4–6 week cycles with 2-week breaks
Neuroprotective Support: 10 mg SC daily × 10–14 days · Repeat monthly or quarterly
Metabolic Resilience: 5–10 mg SC QOD × 4–6 weeks · Combine with exercise, MOTS-c, or GH secretagogues

4.4 Combination / Synergy Protocols

With SS-31: Mitochondrial recovery and ATP enhancement
With MOTS-c: Cellular metabolism and insulin sensitization
With Epitalon: Epigenetic and anti-aging stack

5. Safety & Monitoring

5.1 Tolerability & Adverse Effects

No serious adverse events reported in animal or early-phase trials. Potential for mild injection-site redness or transient fatigue.

5.2 Contraindications

Active malignancy (theoretical caution due to anti-apoptotic mechanisms)
Pregnancy/lactation (lack of safety data)
Use cautiously in insulin-sensitive patients; monitor glucose as needed

5.3 Monitoring Suggestions

Fasting insulin, glucose, or HOMA-IR (optional)
Inflammatory markers (CRP, IL-6 in neurodegenerative protocols)
Patient-reported cognitive/mood/stamina outcomes

6. Clinical Decision Trees

Cognitive complaints? → Yes → 10 mg SC daily × 10 days → Repeat monthly

Mitochondrial dysfunction / fatigue? → Yes → 10–20 mg QOD SC

Insulin resistance or metabolic syndrome? → Yes → 5–10 mg QOD

Anti-aging / longevity protocol? → Yes → Stack with Epitalon + MOTS-c quarterly

Neuroinflammation / stress recovery? → Yes → Humanin + SS-31 combo

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

Humanin, and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — Humanin (HN) Clinical Reference Guide

1. Yen, K., et al. (2013). The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY), 5(2), 63–75.

2. Muzumdar, R. H., et al. (2009). Humanin: a novel central regulator of peripheral insulin action. PLOS ONE, 4(7), e6334.

3. Hashimoto, Y., et al. (2001). Humanin inhibits neuronal cell death by interacting with a receptor complex. Nature, 423(6938), 456–60.

4. Cobb, L. J., et al. (2016). Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging (Albany NY), 8(4), 796–809.

5. Lee, C., et al. (2015). The mitochondrial-derived peptide humanin improves insulin sensitivity in mice with diet-induced obesity. Endocrinology, 156(3), 923–36.

6. Hashimoto, Y., et al. (2005). Humanin inhibits neuronal cell death by interacting with Bax. Nature, 430(7003), 96–99.